Literature DB >> 12707978

Dendritic cells in hyperplastic thymuses from patients with myasthenia gravis.

Yuriko Nagane1, Kimiaki Utsugisawa, Daiji Obara, Munehisa Yamagata, Hideo Tohgi.   

Abstract

To investigate the role of dendritic cells (DCs) in the hyperplastic myasthenia gravis (MG) thymus, we studied the frequency and distribution of three mature DC phenotypes (CD83(+)CD11c(+), CD86(+)CD11c(+), and HLA-DR(+)CD11c(+)) in samples from patients with MG whose symptoms dramatically improved following thymectomy and in non-MG control thymuses. In hyperplastic MG thymuses, mature DCs were much more numerous in nonmedullary areas, such as the subcapsular/outer cortex; around the germinal centers; and in extralobular connective tissue, particularly around blood vessels. Mature DCs strongly coexpressed CD44 and appeared to be components of a CD44-highly positive (CD44(high)) cell population migrating from the vascular system. Furthermore, in the hyperplastic MG thymus, the expression of secondary lymphoid-tissue chemokine (SLC) markedly increased especially around extralobular blood vessels, where the CD44(high) cell population accumulated. These findings suggest that DCs may migrate into the hyperplastic thymus from the vascular system via mechanisms that involve CD44 and SLC. DCs may present self-antigens, thereby promoting the priming and/or boosting of potentially autoreactive T cells against the acetylcholine receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707978     DOI: 10.1002/mus.10362

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.

Authors:  Rozen Le Panse; Géraldine Cizeron-Clairac; Jacky Bismuth; Sonia Berrih-Aknin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  MGTX extension study longitudinally favors early thymectomy in non-thymomatous young-adult patients with AChR antibody-positive myasthenia gravis.

Authors:  Tetsuya Akaishi; Masakatsu Motomura; Masashi Aoki; Kimiaki Utsugisawa
Journal:  Ann Transl Med       Date:  2019-09

3.  Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  J Autoimmun       Date:  2014-01-02       Impact factor: 7.094

4.  Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis.

Authors:  Matthew N Meriggioli; Jian Rong Sheng; Liangcheng Li; Bellur S Prabhakar
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 5.  Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update.

Authors:  Noushin Lotfi; Rodolfo Thome; Nahid Rezaei; Guang-Xian Zhang; Abbas Rezaei; Abdolmohamad Rostami; Nafiseh Esmaeil
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.